Forbes March 2, 2021
The U.S. has never had a publicly funded, independent health technology assessment organization to evaluate prescription drugs, diagnostics, and devices, and subsequently provide recommendations on pricing and reimbursement. This may soon change as the Biden Administration considers creating such a national health technology assessment entity with advisory powers.
Details are sparse regarding the Biden Administration’s possible plans to launch a national evidence gathering entity that would advise public programs like Medicare on drug, diagnostic, and device pricing and reimbursement issues. In passing, the Biden team has mentioned Germany’s drug pricing watchdog, the Institute for Quality and Efficiency in Health Care (IQWiG) as a possible template.
The federal government does have the Agency for Healthcare Research and Quality (AHRQ) and the...
Today's Sponsors
Today's Sponsor